Acetazolamide-13C2,d3

Acetazolamide-13C2,d3

• UNSPSC Description: Acetazolamide-13C2,d3 is the 13C- and deuterium labeled Acetazolamide. Acetazolamide is a carbonic anhydrase (CA) IX inhibitor with an IC50 of 30 nM for hCA IX[1]. Diuretic effects[4].
• Target Antigen: Autophagy; Carbonic Anhydrase; Isotope-Labeled Compounds
• Type: Isotope-Labeled Compounds
• Related Pathways: Autophagy;Metabolic Enzyme/Protease;Others
• Applications: Cancer-programmed cell death
• Field of Research: Cardiovascular Disease; Cancer
• Solubility: 10 mM in DMSO
• Smiles: O=[13C](NC1=NN=C(S(=O)(N)=O)S1)[13C]([2H])([2H])[2H]
• Molecular Weight: 227.25
• References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-223.|[2]Bayat Mokhtari R, et al. Acetazolamide potentiates the anti-tumor potential of HDACi, MS-275, in neuroblastoma. BMC Cancer. 2017 Feb 24;17(1):156.|[3]Gao H, et al. Combined treatment with acetazolamide and cisplatin enhances chemosensitivity in laryngeal carcinoma Hep-2 cells. Oncol Lett. 2018 Jun;15(6):9299-9306.|[4]Hou Z, et al. Dual-tail approach to discovery of novel carbonic anhydrase IX inhibitors by simultaneously matching the hydrophobic and hydrophilic halves of the active site. Eur J Med Chem. 2017 May 26;132:1-10.|[5]Kassamali R, et al. Acetazolamide: a forgotten diuretic agent. Cardiol Rev. 2011 Nov-Dec;19(6):276-8.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported